|
Getting your Trinity Audio player ready...
|
Drugmakers GlaxoSmithKline (“GSK”) and Boehringer Ingelheim have managed to persuade a Chicago jury to reject a woman’s claim that the heartburn drug Zantac caused her cancer. Although the companies won this case, it is the first of thousands of such lawsuits to go to trial in the USA.
As Professor Carl Heneghan and Dr. Tom Jefferson explain, this is not the first time GSK has been mired in litigation.
Let’s not lose touch…Your Government and Big Tech are actively trying to censor the information reported by The Exposé to serve their own needs. Subscribe now to make sure you receive the latest uncensored news in your inbox…
The Real Winners
By Prof. Carl Heneghan and Dr. Tom Jefferson
This week, GSK won a much-needed victory in a $640 million cancer lawsuit over the heartburn drug Zantac. However, thousands of lawsuits are still due to go to trial in the US. And there are thousands more to come.
Zantac became available in the 1980s before becoming an over-the-counter product. At one point, it was the world’s top-selling medicine, with more than $1 billion in annual sales. Its ownership has changed hands. Sanofi, Zantac’s current owner, has paid over $100 million to settle Zantac cancer lawsuits.
In 2019, GSK recalled Zantac stocks “due to possible contamination with an impurity NDMA, which has genotoxic and carcinogenic potential.” Having already settled some cases before going to trial and facing over 70,000 field Zantac cases, GSK went on the offensive to dismiss claims the drug caused colorectal cancer.
Recent cohort evidence reports use was not associated with an increased risk of cancer but with a caveat that further research is needed on the long-term association. Inconsistent results across different countries prevented ruling out a potential association with cancer.
The lawsuits claim that GSK knew about the dangers of NDMA but failed to adequately warn the public. This is not the first time GSK has been mired in litigation: it has previously faced allegations of unethical and unsafe business practices.
Zofran (ondansetron) was prescribed for morning sickness even though the US Food and Drug Administration (“FDA”) had never approved it for this indication. Families who suffered congenital disabilities after taking Zofran while pregnant sued GSK as it marketed the drug during pregnancy without FDA approval. In 2021, GSK “scored a big win” in litigation. It argued that the FDA had repeatedly rejected pregnancy warnings. Further attempts to the US appeals court were thwarted as in 2023, it stated it won’t revive Zofran congenital disability cases.
Back in 2012, GSK paid $3 billion to resolve its criminal and civil liability arising from the unlawful promotion of certain prescription drugs and its failure to report safety data.
In 2010, Avandia (Rosiglitazone) was recalled. GSK had long known about the increased risk of heart disease, but it “used its power to silence scientists rather than protecting its customers by bringing the harm to light.”
As we have often said, not much gets by the Trust the Evidence office. In 2006, writing in the BMJ Prof. Heneghan pointed out that “despite the population being at low risk of heart failure (10-year risk 0.33%), a significant increase (0.4%) in heart failure was seen in the rosiglitazone group compared with placebo (7.03, 1.60 to 30.9, number needed to harm at three years 250).” Yet it took until 2010 to ask questions about what went wrong.
Perhaps the most egregious example of bad behaviour is GSK’s withholding of trial data for the drug Paroxetine, known as Paxil in North America and Seroxat in the UK.
As part of the largest healthcare fraud settlement in US History, GSK was fined for unlawfully promoting the product to under-18s, data withholding, and misbranding the product, among other illegal practices.
(The withheld ‘Study 329’ has its own Wikipedia page that’s worth a read).
We could go on about GSK’s woes. For example, in 2014, a Chinese court ordered GSK to pay $492 million for bribing doctors in China to use their products.
Sir (Sir) Patrick Vallance (Sir squared) joined the company in 2006 as head of drug discovery and was president of Research and Development at GSK from 2012 to 2018. Everyone knows where he went next.
The latest news is that GSK has sold its remaining stake in Haleo, the maker of Panadol painkillers and Sensodyne toothpaste, raising £1.25bn. This underlines GSK’s strategy to focus on the most profitable drugs.
Profits on newer drugs are excessive; they distort the development market and ensure the focus is on blockbuster sales. In the US, the price of prescription drugs increased from roughly $1,400 a year in 2008 to over $150,000 a year in 2021. The UK’s NHS spent £13 billion on just ten medicines in the decade up to 2022. Global Justice Now estimated drug companies made up to £12.6 billion through “extreme profiteering.” Their report estimated the cost of these ten drugs to the NHS was “well below 10 per cent of the price charged.”
The fines, though, are insignificant in the context of GSK revenues – for the twelve months ending March 2024, revenues were $38.7 billion, a 22% increase year on year as vaccine and cancer drug sales soared.
The reputational damage to GSK has done little to the careers of those who have overseen these woes: when it comes to drug companies, it seems that crime really does pay.
This post was written by two geezers who may be awarded the Order of the Squared Golden Boot.
About the Authors
Carl Heneghan is a professor of Evidence-based Medicine at the University of Oxford, Director of the Centre for Evidence-Based Medicine (“CEBM”) and NHS Urgent Care general practitioner who regularly appears in the media. Tom Jefferson is a clinical epidemiologist and a Senior Associate Tutor at the University of Oxford. Together they publish articles on a Substack page titled ‘Trust the Evidence’.
The Expose Urgently Needs Your Help…
Can you please help to keep the lights on with The Expose’s honest, reliable, powerful and truthful journalism?
Your Government & Big Tech organisations
try to silence & shut down The Expose.
So we need your help to ensure
we can continue to bring you the
facts the mainstream refuses to.
The government does not fund us
to publish lies and propaganda on their
behalf like the Mainstream Media.
Instead, we rely solely on your support. So
please support us in our efforts to bring
you honest, reliable, investigative journalism
today. It’s secure, quick and easy.
Please choose your preferred method below to show your support.
Categories: Breaking News, World News
This geezer thinks you’re a shoe-in for the golden boot award. Great article. Thanks very much.
Hi Nathan, I’d be happy to accept anything made of gold 🙂
[…] Go to Source Follow altnews.org on Telegram […]
[…] Read More: GSK’s litigation woes for selling harmful drugs continue […]
[…] GSK’s litigation woes for selling harmful drugs continue Drugmakers GlaxoSmithKline (“GSK”) and Boehringer Ingelheim have managed to persuade a Chicago jury to reject a woman’s claim that the heartburn drug Zantac caused her cancer. Although the companies won this case, it is the first of thousands of such lawsuits to go to trial in the USA. […]
[…] GSK’s litigation woes for selling harmful drugs continue Drugmakers GlaxoSmithKline (“GSK”) and Boehringer Ingelheim have managed to persuade a Chicago jury to reject a woman’s claim that the heartburn drug Zantac caused her cancer. Although the companies won this case, it is the first of thousands of such lawsuits to go to trial in the USA. […]